Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

Table 6

Coexpression of MHC class I components with tumorantigens.

	p53^+	SP17^+	Survivin^+	WT1^+	NY-ESO1^+	Tumorantigen^+2
	n = 80	n = 116	n = 152	n = 89	n = 20	n = 173
	n/total (%)	n/total (%)	n/total (%)	n/total (%)	n/total (%)	n/total (%)
HLA- 𝐴^+ 𝛽2𝑚^+	52/80	64/116	80/152	50/89	13/20	96/173
n = 98	(65.0)	(55.2)	(52.6)	(56.2)	(65.0)	(55.0)
HLA-B/ 𝐶^+ 𝛽2𝑚^+	62/78	94/116	111/151	67/89	15/20	129/171
n = 136	(79.5)	(81.0)	(73.5)	(75.3)	(75.0)	(75.4)
MHC class 𝐼^+	66/80	96/116	117/152	72/89	16/20	136/173
n = 143	(82.5)	(82.8)	(77.0)	(80.9)	(80.0)	(78.4)
All 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠^1	66/174	96/178	117/169	72/167	16/175	136/183
n = 183	(37.9)	(53.9)	(69.2)	(43.1)	(9.1)	(74.3)

¹Antigen⁺ and MHC class I⁺ in all subgroup patients (n = 183); ²≥1 tumorantigen expression.